Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, controlled trial design. It was conducted with a main purpose of evaluating the effect of thiamine supplementation on serum lactate and lactate-pyruvate ratio after surgery as direct indicators of tissue perfusion and indirect markers of energy substrate availability for effective mitochondrial function and intubation time as clinical outcome.


Clinical Trial Description

All patients who undergo open cardiac surgery for their congenital heart disease on the research period will be recruited consecutively and evaluated according to the study criteria. Parents or guardians were explained about the procedure. Agreement will be concluded by signing the informed consent. Baseline data including age, nutritional status, diagnosis, types of heart disease (cyanotic or acyanotic), restrictive or non restrictive pulmonary blood flow heart disease, pre-surgical peripheral saturation, pulmonary hypertension and any syndromes associated with heart disease will be recorded on the study sheets.

Patients will be randomised using block randomisation procedure with a block size of 4 on treatment and control group. Included participants will be marked by specific randomisation number by a research assistant physician who is not involved in patients' management. A pharmacist will acquire and open a prepared envelope containing the randomisation number. The patients, parents/guardians, research physicians, other physicians or paramedics involved in patients' treatment will be blinded.

Placebo (Intravenous Normal Saline) and intravenous thiamine (2 mg/kg) will be administered at induction time, 1 hours after surgery and once everyday for three days by pharmacist according to randomization result. All subject are given oral T3 supplementation (1 mcg/kg) every 6 hours by pharmacist as research protocol. Oral T3 supplementations are given every 6 hours, started from induction time until 11 doses (60 hours until the first dose). Drugs is diluted with 2.5 cc aqua and administerednisterd using nasogastric tube.

Blood will be withdrawn from arterial line access for 2.5 cc in order to test thiamine, lactate, and pyruvate concentration, as well as, measuring LDH and PDH activity. Thiamine will be examined from blood plasma using liquid chromatography tandem mass spectometry. Thiamine concentration below ≤ 7 nmol/L is considered low. PDH will be examined from Peripheral Blood Mononuclear Cells (PBMCs) which will be isolated from fresh blood. PDH activity will be tested after breaking cell membrane to initiate mitochondria lysis, this process will be done by immunocapture and micro-plate based assay. Lactate and pyruvate measurement will be tested using an enzymatic kit specific for lactate and pyruvate called Sigma Aldrich reagent. Thiamine concentration, lactate concentration, pyruvate concentration, LDH and PDH activity is going to be measured at 4 time; induction time, one hour, 24 hours, 72 hours after aortic clamp removal.

Measurement of blood gas analysis, blood glucose, central vein saturation and oxygen extraction ratio will be performed at induction time, 1 hours, and 12 hours post-surgery.

Organ functions evaluation was performed by serially measuring SGOT and SGPT (liver function) as well as ureum and creatinine (renal function) on ICU admission.

Echocardiography evaluation will be done on the first, second and third day after surgery to assess the patient's ejection fraction, stroke volume, cardiac volume and index, tricuspid annular plane systolic excursion (TAPSE), left heart diastolic functions and SVRI calculation. It will be done by 2 research cardiologists.

Post-surgical managements will be decided according to the paediatric ICU National Cardiovascular Center Harapan Kita treatment protocols. Inotropic concentration will be evaluated by inotropic and vasoactive-inotropic scoring every 6 hours in the first 24 hours and every 12 hours after the second and third 24 hours. The amount of diuretics used will be calculated 72 hours after ICU admission. Peritoneal dialysis and continuous veno-venous hemofiltration (CVVH) is going to be assessed by means of the length of therapy, renal function and fluid balance. Decision to extubate will be carried out by a physician responsible according to the treatment protocols. Every reintubation is going to be recorded as number and length of intubation. The length of ICU and hospital stay and mortality will be evaluated in both study groups.

Operative data such as Aristotle score, residual lesions presence, open thorax on ICU admission, CPB duration, Aox duration and a number of procedures during CPB including ultrafiltration, hypothermia and hemodilution is going to be recorded in the research sheets. History of medication used which may interfere with the function of thyroid such as steroids, dopamine and amiodarone will also be recorded.

There will be one physician who know the subject's allocation. This physician is not involve in any kind of patients' treatment and act as the study supervisor to evaluate if any suspicion on drug adverse reactions occurred. Drug adverse reaction is going to be monitored by evaluating heart rhythm, heart rate, blood pressure and peripheral temperature for every 6 hours in the first 24 hours and every 12 hours in the second and third 24 hours of ICU treatment. The criteria of drug adverse reaction are stated in the adverse effects form; they are tachycardia, arrhythmia, hypertension and refractory hyperthermia. Any suspicion of the presence of drug adverse effect is going to be recorded in the form and reported to the supervising doctor for further analysis. Management on this reaction will be done by the ICU treating doctor ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04453761
Study type Interventional
Source National Cardiovascular Center Harapan Kita Hospital Indonesia
Contact
Status Active, not recruiting
Phase Phase 4
Start date July 1, 2018
Completion date December 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04992793 - Paediatric Brain Injury Following Cardiac Interventions
Recruiting NCT05213598 - Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
Completed NCT04136379 - Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD
Completed NCT04814888 - 3D Airway Model for Pediatric Patients
Recruiting NCT04920643 - High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery N/A
Completed NCT05934578 - Lymphatic Function in Patients With Fontan Circulation: Effect of Physical Training N/A
Recruiting NCT06041685 - Effect of Local Warming for Arterial Catheterization in Pediatric Anesthesia N/A
Recruiting NCT05902013 - Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation N/A
Not yet recruiting NCT05687292 - Application of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery
Not yet recruiting NCT05524324 - Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT N/A
Completed NCT02746029 - Cardiac Murmurs in Children: Predictive Value of Cardiac Markers
Completed NCT03119090 - Fontan Imaging Biomarkers (FIB) Study
Completed NCT02537392 - Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease N/A
Recruiting NCT02258724 - Swiss National Registry of Grown up Congenital Heart Disease Patients
Completed NCT01966237 - Milrinone Pharmacokinetics and Acute Kidney Injury
Terminated NCT02046135 - Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery Phase 2
Recruiting NCT01184404 - Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery N/A
Completed NCT01548950 - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension N/A
Completed NCT01178710 - Effect of Simvastatin on Cardiac Function N/A